Related references
Note: Only part of the references are listed.DNA Methylation Predicts Recurrence From Resected Stage III Proximal Colon Cancer
Joong Bae Ahn et al.
CANCER (2011)
Benefits of Interferon-β and Temozolomide Combination Therapy for Newly Diagnosed Primary Glioblastoma With the Unmethylated MGMT Promoter A Multicenter Study
Kazuya Motomura et al.
CANCER (2011)
Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer
Kazuyuki Kawakami et al.
CANCER SCIENCE (2011)
DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma
Brock C. Christensen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis
Julien Laffaire et al.
NEURO-ONCOLOGY (2011)
Molecular Classification of Low-Grade Diffuse Gliomas
Young Ho Kim et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Houtan Noushmehr et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
Martin J. van den Bent et al.
CLINICAL CANCER RESEARCH (2010)
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma
Andreana L. Rivera et al.
NEURO-ONCOLOGY (2010)
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
M. Labussiere et al.
NEUROLOGY (2010)
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2009)
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Sumihito Nobusawa et al.
CLINICAL CANCER RESEARCH (2009)
MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Marc Sanson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Analysis of the IDH1 codon 132 mutation in brain tumors
Joerg Balss et al.
ACTA NEUROPATHOLOGICA (2008)
The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma
Atsushi Natsume et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer
J. Pattamadilok et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
Monika E. Hegi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A Cohort Study of Tumoral LINE-1 Hypomethylation and Prognosis in Colon Cancer
Shuji Ogino et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Malignant gliomas in adults
Patrick Y. Wen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Multiplex ligation-dependent probe amplification - A diagnostic tool for simultaneous identification of different genetic markers in glial tumors
Judith Jeuken et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2006)
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer
Daniel J. Weisenberger et al.
NATURE GENETICS (2006)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors
M Möllemann et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
MGMT: Its role in cancer aetiology and cancer therapeutics
SL Gerson
NATURE REVIEWS CANCER (2004)
Genetic pathways to glioblastoma:: A population-based study
H Ohgaki et al.
CANCER RESEARCH (2004)
Share Paper
